Treatment of nonalcoholic fatty liver disease: role of AMPK. (Q30248230)

13 June 2017

1 reference

title

Treatment of nonalcoholic fatty liver disease: role of AMPK. (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

13 June 2017

1 reference

1 reference

1 reference

Brennan K Smith

1

1 reference

13 June 2017

Katarina Marcinko

2

1 reference

13 June 2017

Eric M Desjardins

3

1 reference

13 June 2017

James S Lally

4

1 reference

13 June 2017

Rebecca J Ford

5

1 reference

13 June 2017

Gregory R Steinberg

6

1 reference

13 June 2017

30 August 2016

1 reference

American Journal of Physiology - Endocrinology and Metabolism

13 June 2017

1 reference

13 June 2017

311

1 reference

13 June 2017

4

1 reference

13 June 2017

E730-E740

1 reference

The subcellular localization of acetyl-CoA carboxylase 2

13 June 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Systematic review: Preventive and therapeutic applications of metformin in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Insulin resistance: a metabolic pathway to chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

A high-fat diet suppresses de novo lipogenesis and desaturation but not elongation and triglyceride synthesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Interplay between FGF21 and insulin action in the liver regulates metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

SR4 Uncouples Mitochondrial Oxidative Phosphorylation, Modulates AMP-dependent Kinase (AMPK)-Mammalian Target of Rapamycin (mTOR) Signaling, and Inhibits Proliferation of HepG2 Hepatocarcinoma Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

COH-SR4 reduces body weight, improves glycemic control and prevents hepatic steatosis in high fat diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Brief intense interval exercise activates AMPK and p38 MAPK signaling and increases the expression of PGC-1alpha in human skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

A Potent and Selective AMPK Activator That Inhibits de Novo Lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Physical exercise prevents and mitigates non-alcoholic steatohepatitis-induced liver mitochondrial structural and bioenergetics impairments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Regulation of AMP-activated protein kinase by natural and synthetic activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Cordycepin prevents hyperlipidemia in hamsters fed a high-fat diet via activation of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMPK: a target for drugs and natural products with effects on both diabetes and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

The ancient drug salicylate directly activates AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

The effects of chronic AMPK activation on hepatic triglyceride accumulation and glycerol 3-phosphate acyltransferase activity with high fat feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Acute regulation of metabolic genes and insulin receptor substrates in the liver of mice by one single bout of treadmill exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Clinical trial success rates of anti-obesity agents: the importance of combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Purple sweet potato anthocyanins attenuate hepatic lipid accumulation through activating adenosine monophosphate-activated protein kinase in human HepG2 cells and obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMP-activated protein kinase beta subunit tethers alpha and gamma subunits via its C-terminal sequence (186-270)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Effect of aerobic exercise training dose on liver fat and visceral adiposity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Boesenbergia pandurata attenuates diet-induced obesity by activating AMP-activated protein kinase and regulating lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Mitochondrial dysfunction in white adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

A small-molecule benzimidazole derivative that potently activates AMPK to increase glucose transport in skeletal muscle: comparison with effects of contraction and other AMPK activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Hepatic steatosis development with four weeks of physical inactivity in previously active, hyperphagic OLETF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

High intensity interval training improves liver and adipose tissue insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

The role of metformin in the management of NAFLD

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Regulation of hepatic fatty acid oxidation and ketone body production

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Involvement of exercise-induced macrophage migration inhibitory factor in the prevention of fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Lack of Adipocyte AMPK Exacerbates Insulin Resistance and Hepatic Steatosis through Brown and Beige Adipose Tissue Function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

From NAFLD in clinical practice to answers from guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Splanchnic lipolysis in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Changes in fat synthesis influenced by dietary macronutrient content

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Nonalcoholic fatty liver disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Metabolite Regulation of Nuclear Localization of Carbohydrate-response Element-binding Protein (ChREBP): ROLE OF AMP AS AN ALLOSTERIC INHIBITOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Disordered lipid metabolism and the pathogenesis of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Inhibition of AMP-Activated Protein Kinase at the Allosteric Drug-Binding Site Promotes Islet Insulin Release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Overexpression of AMPKalpha1 Ameliorates Fatty Liver in Hyperlipidemic Diabetic Rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Folic acid supplementation during high-fat diet feeding restores AMPK activation via an AMP-LKB1-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMPK in Health and Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Cassia tora (Leguminosae) seed extract alleviates high-fat diet-induced nonalcoholic fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Regulation and function of triacylglycerol lipases in cellular metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Cordycepin activates AMP-activated protein kinase (AMPK) via interaction with the γ1 subunit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Structural basis for AMP binding to mammalian AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Structural basis of AMPK regulation by small molecule activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Structure of mammalian AMPK and its regulation by ADP

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Chronic Activation of γ2 AMPK Induces Obesity and Reduces β Cell Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMPK-dependent modulation of hepatic lipid metabolism by nesfatin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Lifestyle intervention involving calorie restriction with or without aerobic exercise training improves liver fat in adults with visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

21 January 2018

Mechanisms of mitophagy

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

AMPKα1 overexpression alleviates the hepatocyte model of nonalcoholic fatty liver disease via inactivating p38MAPK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Caffeine ameliorates high energy diet-induced hepatic steatosis: sirtuin 3 acts as a bridge in the lipid metabolism pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00225.2016

10.1152/AJPENDO.00225.2016

21 January 2018

Identifiers

DOI

1 reference

13 June 2017

1 reference